ACE inhibitors and ARBs: One or the other -- not both -- for high-risk patients
No Thumbnail Available
Meeting name
Sponsors
Date
Journal Title
Format
Article
Subject
Abstract
Avoid prescribing an angiotensin-converting enzyme (ACE) inhibitor and an angiotensin receptor blocker (ARB) for patients at high risk of vascular events or renal dysfunction. The combination does not reduce poor outcomes, and leads to more adverse drug-related events than an ACE inhibitor or ARB alone. Stength of recommendation: B: 1 large, high-quality randomized controlled trial (RCT).
Table of Contents
DOI
PubMed ID
Degree
Thesis Department
Rights
OpenAccess.
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.